SCHEMBL4958819

SCHEMBL4958819

Cc1csc(-c2ncccc2C(=O)c2cccc(F)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
SLC6A7 Q99884 1/20 0.40
MEN1 O00255 2/20 0.39
TSHR P16473 2/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
ALOX15 P16050 1/20 0.39
USP2 O75604 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
POLB P06746 2/20 0.36
GRM1 Q13255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4963366 0.82 HTT (0.42) ALDH1A1NPC1RAB9APOLBMAPT
SCHEMBL4958946 0.79 RAB9A (0.43) KMT2ASLC6A7ALDH1A1GAACES2
SCHEMBL4958812 0.73 ABL1 (0.40) KMT2AMEN1USP2CYP1A2CYP3A4
SCHEMBL4957447 0.72 PTGS2 (0.57)
SCHEMBL4960341 0.72 USP2 (0.52) KMT2AMEN1TSHRALDH1A1USP2
SCHEMBL9397130 0.68 POLB (0.54) KMT2AMEN1TSHRALDH1A1GAA
SCHEMBL8586217 0.67 KMT2A (0.66) KMT2AMEN1ALDH1A1USP2CYP1A2
SCHEMBL14415753 0.67 CES2 (0.52) KMT2AMEN1TSHRALDH1A1GAA
SCHEMBL806857 0.66 KCNK3 (0.64) KMT2AMEN1TSHRALDH1A1CES2
SCHEMBL4136803 0.66 CES2 (0.50) KMT2AMEN1TSHRALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542972-A4 CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-01-23 EP disclosed
US-20070238735-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITRODMED, INC. (US) 2007-10-11 US disclosed
US-7244753-B2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2007-07-17 US disclosed
EP-1542972-A2 CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2005-06-22 EP disclosed
US-20040072883-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. 2004-04-15 US disclosed
WO-2004010945-A2 CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072883-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 KMT2A 3968/4885SLC6A7 3032/4885MEN1 4470/4885
US-20070238735-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGS1 KMT2A 3840/4885SLC6A7 3063/4885MEN1 4597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.